Cadila Healthcare re-appoints Dr Sharvil P Patel as Managing Director
Ahmedabad: Cadila Healthcare has announced the re-appointment of Dr. Sharvil P. Patel as the Managing Director of the company for a further period of 5 (five) year effective from April 1, 2022 to March 31, 2027.
The Company will seek approval of members in an extra ordinary general meeting, it added.
At present, Dr. Sharvil Patel is the Managing Director of the Company, which is one of the leading global healthcare providers and the 4th largest pharmaceutical company in India. He also officiates as the Chairman on the Board of Zydus Wellness Ltd., which has a basket of niche products and iconic brands such as Sugar Free, Everyuth, Nutralite, Com plan, Glucon D and Nycil.
With a specialisation in Chemical and Pharmaceutical Sciences from the University of Sunderland, U.K., and a doctorate also from the same university for his research work in Breast Cancer at Johns Hopkins, Bayview Medical Centre, USA, Dr. Sharvil Patel combines both pharma and research expertise. He was conferred the '40 Under 40 Most Influential Asians' Award by the Asian Business & Social Forum 2018 (ABSF) and the Young Business Leader '40 under Forty' Award by ET Now in 2017.
Recently he has also been conferred the 'The Economic Times Most Promising Business Leaders of Asia 2020-21' Award, 'GenNext Entrepreneur of the Forbes India Leadership Awards (FILA) 2020-21' by the Forbes India and 'Young Turks Award' by India Pharma Awards 2021.
Supporting the nation in the fight against the novel Coronavirus, Zydus Cadila is at the forefront manufacturing therapies and lifesaving drugs, exploring new therapy options through research, discovering vaccines and manufacturing diagnostic kits. The company also received the emergency use authorization for the world's first DNA plasmid vaccine ZyCoV-D.
Read also: USFDA nod to Zydus to market generic version of Vigabatrin
